Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
40
BBLG Quote, Financials, Valuation and Earnings
Last price:
$1.90
Seasonality move
:
-35.57%
Day range:
$1.92 - $2.03
52-week range:
$1.30 - $7.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.18x
Volume:
18.9K
Avg. volume:
37.9K
1-year change:
-70.37%
Market cap:
$1.1M
Revenue:
--
EPS (TTM):
-$6.71
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBLG
Bone Biologics Corp.
|
-- | -$1.23 | -- | -89% | $22.25 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBLG
Bone Biologics Corp.
|
$2.03 | $22.25 | $1.1M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$2.80 | $0.85 | $352.8M | 4.70x | $0.80 | 0% | 5.44x |
|
NNVC
NanoViricides, Inc.
|
$1.25 | $7.00 | $22.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.91 | $2.00 | $752.1K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.22 | $7.00 | $7.3M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBLG
Bone Biologics Corp.
|
-- | 2.843 | -- | 18.09x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBLG
Bone Biologics Corp.
|
-- | -$715.3K | -86.54% | -86.54% | -- | -$591.4K |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Bone Biologics Corp. vs. Competitors
-
Which has Higher Returns BBLG or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Bone Biologics Corp.'s net margin of -255.85%. Bone Biologics Corp.'s return on equity of -86.54% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital BBLGBone Biologics Corp.-- -$0.37 $6M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About BBLG or NBY?
Bone Biologics Corp. has a consensus price target of $22.25, signalling upside risk potential of 997.68%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -69.64%. Given that Bone Biologics Corp. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Bone Biologics Corp. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BBLGBone Biologics Corp.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is BBLG or NBY More Risky?
Bone Biologics Corp. has a beta of 0.519, which suggesting that the stock is 48.136% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock BBLG or NBY?
Bone Biologics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Bone Biologics Corp. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBLG or NBY?
Bone Biologics Corp. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Bone Biologics Corp.'s net income of -$666.7K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Bone Biologics Corp.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 4.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics Corp. is -- versus 5.44x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBLGBone Biologics Corp.-- -- -- -$666.7K NBYNovaBay Pharmaceuticals, Inc.5.44x 4.70x $521K -$1.3M
-
Which has Higher Returns BBLG or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Bone Biologics Corp.'s net margin of --. Bone Biologics Corp.'s return on equity of -86.54% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital BBLGBone Biologics Corp.-- -$0.37 $6M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About BBLG or NNVC?
Bone Biologics Corp. has a consensus price target of $22.25, signalling upside risk potential of 997.68%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 460%. Given that Bone Biologics Corp. has higher upside potential than NanoViricides, Inc., analysts believe Bone Biologics Corp. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BBLGBone Biologics Corp.0 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is BBLG or NNVC More Risky?
Bone Biologics Corp. has a beta of 0.519, which suggesting that the stock is 48.136% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock BBLG or NNVC?
Bone Biologics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bone Biologics Corp. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBLG or NNVC?
Bone Biologics Corp. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Bone Biologics Corp.'s net income of -$666.7K is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Bone Biologics Corp.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics Corp. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBLGBone Biologics Corp.-- -- -- -$666.7K NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns BBLG or OGEN?
Oragenics, Inc. has a net margin of -- compared to Bone Biologics Corp.'s net margin of --. Bone Biologics Corp.'s return on equity of -86.54% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital BBLGBone Biologics Corp.-- -$0.37 $6M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About BBLG or OGEN?
Bone Biologics Corp. has a consensus price target of $22.25, signalling upside risk potential of 997.68%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 118.82%. Given that Bone Biologics Corp. has higher upside potential than Oragenics, Inc., analysts believe Bone Biologics Corp. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BBLGBone Biologics Corp.0 0 0 OGENOragenics, Inc.1 0 0 -
Is BBLG or OGEN More Risky?
Bone Biologics Corp. has a beta of 0.519, which suggesting that the stock is 48.136% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock BBLG or OGEN?
Bone Biologics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bone Biologics Corp. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBLG or OGEN?
Bone Biologics Corp. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Bone Biologics Corp.'s net income of -$666.7K is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Bone Biologics Corp.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics Corp. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBLGBone Biologics Corp.-- -- -- -$666.7K OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns BBLG or PTN?
Palatin Technologies has a net margin of -- compared to Bone Biologics Corp.'s net margin of --. Bone Biologics Corp.'s return on equity of -86.54% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBLGBone Biologics Corp.-- -$0.37 $6M PTNPalatin Technologies-- -- -- -
What do Analysts Say About BBLG or PTN?
Bone Biologics Corp. has a consensus price target of $22.25, signalling upside risk potential of 997.68%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Bone Biologics Corp., analysts believe Palatin Technologies is more attractive than Bone Biologics Corp..
Company Buy Ratings Hold Ratings Sell Ratings BBLGBone Biologics Corp.0 0 0 PTNPalatin Technologies0 0 0 -
Is BBLG or PTN More Risky?
Bone Biologics Corp. has a beta of 0.519, which suggesting that the stock is 48.136% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock BBLG or PTN?
Bone Biologics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bone Biologics Corp. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBLG or PTN?
Bone Biologics Corp. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Bone Biologics Corp.'s net income of -$666.7K is higher than Palatin Technologies's net income of --. Notably, Bone Biologics Corp.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics Corp. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBLGBone Biologics Corp.-- -- -- -$666.7K PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns BBLG or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Bone Biologics Corp.'s net margin of --. Bone Biologics Corp.'s return on equity of -86.54% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital BBLGBone Biologics Corp.-- -$0.37 $6M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About BBLG or TOVX?
Bone Biologics Corp. has a consensus price target of $22.25, signalling upside risk potential of 997.68%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3121.35%. Given that Theriva Biologics, Inc. has higher upside potential than Bone Biologics Corp., analysts believe Theriva Biologics, Inc. is more attractive than Bone Biologics Corp..
Company Buy Ratings Hold Ratings Sell Ratings BBLGBone Biologics Corp.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is BBLG or TOVX More Risky?
Bone Biologics Corp. has a beta of 0.519, which suggesting that the stock is 48.136% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock BBLG or TOVX?
Bone Biologics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bone Biologics Corp. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBLG or TOVX?
Bone Biologics Corp. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Bone Biologics Corp.'s net income of -$666.7K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Bone Biologics Corp.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bone Biologics Corp. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBLGBone Biologics Corp.-- -- -- -$666.7K TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 3.51% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 1.79% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 5.81% over the past day.
